These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11953871)

  • 1. 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model.
    Li Y; Rizvi SM; Ranson M; Allen BJ
    Br J Cancer; 2002 Apr; 86(7):1197-203. PubMed ID: 11953871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2.
    Allen BJ; Tian Z; Rizvi SM; Li Y; Ranson M
    Br J Cancer; 2003 Mar; 88(6):944-50. PubMed ID: 12644835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer.
    Qu CF; Song EY; Li Y; Rizvi SM; Raja C; Smith R; Morgenstern A; Apostolidis C; Allen BJ
    Clin Exp Metastasis; 2005; 22(7):575-86. PubMed ID: 16475028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model.
    Abbas Rizvi SM; Li Y; Song EY; Qu CF; Raja C; Morgenstern A; Apostolidis C; Allen BJ
    Cancer Biol Ther; 2006 Apr; 5(4):386-93. PubMed ID: 16575210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
    Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
    Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted alpha therapy for cancer.
    Allen BJ; Raja C; Rizvi S; Li Y; Tsui W; Zhang D; Song E; Qu CF; Kearsley J; Graham P; Thompson J
    Phys Med Biol; 2004 Aug; 49(16):3703-12. PubMed ID: 15446799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
    McDevitt MR; Barendswaard E; Ma D; Lai L; Curcio MJ; Sgouros G; Ballangrud AM; Yang WH; Finn RD; Pellegrini V; Geerlings MW; Lee M; Brechbiel MW; Bander NH; Cordon-Cardo C; Scheinberg DA
    Cancer Res; 2000 Nov; 60(21):6095-100. PubMed ID: 11085533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with 213Bi-conjugates.
    Li Y; Abbas Rizvi SM; Blair nee Brown JM; Cozzi PJ; Qu CF; Ow KT; Tam PN; Perkins AC; Russell PJ; Allen BJ
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):896-908. PubMed ID: 15465208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
    J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of metastasis by inhibition of the urokinase receptor.
    Crowley CW; Cohen RL; Lucas BK; Liu G; Shuman MA; Levinson AD
    Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5021-5. PubMed ID: 8389464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers.
    Allen BJ; Rizvi S; Li Y; Tian Z; Ranson M
    Crit Rev Oncol Hematol; 2001; 39(1-2):139-46. PubMed ID: 11418311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human prostate tumor angiogenesis in nude mice: metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells.
    Wilson MJ; Sinha AA
    Anat Rec; 1997 Sep; 249(1):63-73. PubMed ID: 9294650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells.
    Ranson M; Tian Z; Andronicos NM; Rizvi S; Allen BJ
    Breast Cancer Res Treat; 2002 Jan; 71(2):149-59. PubMed ID: 11881911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma.
    Stutchbury TK; Al-Ejeh F; Stillfried GE; Croucher DR; Andrews J; Irving D; Links M; Ranson M
    Mol Cancer Ther; 2007 Jan; 6(1):203-12. PubMed ID: 17237280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor beta1 stimulates urokinase plasminogen activator system on prostate cancer cells.
    Unlü A; Leake RE
    Int J Biol Markers; 2003; 18(2):147-51. PubMed ID: 12841684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis.
    Boyd DD; Kim SJ; Wang H; Jones TR; Gallick GE
    Am J Pathol; 2003 Feb; 162(2):619-26. PubMed ID: 12547719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity of human prostate cancer cell lines in vitro and induction of apoptosis using 213Bi-Herceptin alpha-conjugate.
    Li Y; Cozzi PJ; Qu CF; Zhang DY; Abbas Rizvi SM; Raja C; Allen BJ
    Cancer Lett; 2004 Mar; 205(2):161-71. PubMed ID: 15036648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
    Nishikawa M; Stapleton PP; Freeman TA; Gaughan JP; Matsuda T; Daly JM
    J Am Coll Surg; 2004 Sep; 199(3):428-35. PubMed ID: 15325613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
    Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters.
    Song YJ; Qu CF; Rizvi SM; Li Y; Robertson G; Raja C; Morgenstern A; Apostolidis C; Perkins AC; Allen BJ
    Cancer Lett; 2006 Mar; 234(2):176-83. PubMed ID: 15961220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.